You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. NURIX THERAPEUTICS INC

Nurix Therapeutics Inc XNAS: NRIX

Nurix Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Weak Stock
Download real time

11.21 0.66 (6.26%)

62.08% Fall from 52W High

665.0K XNAS Volume

XNAS 22 Apr, 2025 1:11 PM (EDT)

Watchlist

Portfolio

Share

Nurix Therapeutics Inc Key Metrics

Default

Market Capitalization

Below industry Median
854.6

PE TTM

Negative PE TTM
-4.1

PEG TTM

Below industry Median
0.1

Price to Book

Below industry Median
1.6

Institutional holding current Qtr %

High in industry
107.3

Revenue Growth Qtr YoY %

Below industry Median
11.3

Operating Revenue growth TTM %

Negative Operating Revenue growth TTM %
-30.3

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-35.7

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-44

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-408.9

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

-42.1

ROE Annual %

Negative ROE Annual %
-53.2

RoA Annual %

Negative RoA Annual %
-37.8
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Low Financial Strength
22.2 / 100
Valuation Score
Expensive Valuation
13.2 / 100
Momentum Score
Technically Bearish
26.8 / 100
Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM
Analyst Price Target
30
1Yr Price target upside is 168%
17 analysts

13

S

11

W

1

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Nurix Therapeutics Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Nov '23Nov '24Nov '25Nov '260100200300Actual RevenueAvg. Estimate
Miss

Nurix Therapeutics Inc's Revenue was lower than average estimate 2 times in past 2 years

EPS forecast

Current EPS
-2.9
Avg. Estimate
-3.1
Low Estimate
-3.6
High Estimate
-2.8
Current EPS
Avg. Estimate
Miss

EPS is expected to reduce by 8.0% in FY25

Consensus Recommendation

17 ANALYST Recommendations
BUY

Created with Highcharts 7.2.22Hold5Buy10Strong Buy

The consensus recommendation from 17 analysts for Nurix Therapeutics Inc is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Nurix Therapeutics Inc Stock Analysis

Nurix Therapeutics Inc stock analysis with key metrics, changes, and trends.

Nurix Therapeutics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$54.55 M29.15%negative

Annual Revenue fell 29.15%, in the last year to $54.55 M. Its sector's average revenue growth for the last fiscal year was 7.49%.

Annual Net Profit$193.57 M34.47%negative

Annual Net Profit fell 34.47% in the last year to $193.57 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio-4.1-negative

Price to Earning Ratio is -4.1, which is negative.

Stock Price$11.21-17.51%negative

Stock Price fell 17.51% and underperformed its sector by 26.5% in the past year.

Quarterly Revenue$18.45 M11.26%positive

Quarterly Revenue rose 11.26% YoY to $18.45 M. Its sector's average revenue growth YoY for the quarter was 5.79%.

Quarterly Net profit$56.35 M35.73%negative

Quarterly Net profit fell 35.73% YoY to $56.35 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

Debt to Equity Ratio0.05-positive

Debt to Equity Ratio of 0.05 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-53.22 %-53.22%negative

Return on Equity(ROE) for the last financial year was -53.22%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding68.23 %-1.25%negative

Mutual Fund Holding decreased by 1.25% in the last quarter to 68.23.

Institutional Holding107.29 %0.02%positive

Institutional Holding increased by 0.02% in the last quarter to 107.29.

VIEW LESS


Loading data..

Nurix Therapeutics Inc - Company Profile

What does Nurix Therapeutics Inc do?

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Nurix Therapeutics Inc Management structure

All Gross Remunerations are in USD
Dr. Arthur T. Sands, M.D.,PhD
Director, President and Chief Executive Officer
5.81 M
2024
Gross Remuneration
Year
Dr. Gwenn Hansen, PhD
Chief Scientific Officer
2.03 M
2024
Gross Remuneration
Year
Dr. Christine Ring, J.D.,PhD
Chief Legal Officer, Chief Compliance Officer and Secretary
2.02 M
2024
Gross Remuneration
Year
Mr. Hans van Houte
Chief Financial Officer and Principal Accounting Officer
2.02 M
2024
Gross Remuneration
Year

Nurix Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Dr. Roy D. Baynes, M.D.,PhD
Director
-
2025
Gross Remuneration
Year

Nurix Therapeutics Inc FAQ

How is Nurix Therapeutics Inc today?
Nurix Therapeutics Inc today is trading in the green, and is up by 6.26% at 11.21.
Nurix Therapeutics Inc is currently trading up 6.26% on an intraday basis. In the past week the stock rose 13.81%. stock has been down -42.81% in the past quarter and fell -17.51% in the past year. You can view this in the overview section.